Poster Session B
Systemic lupus erythematosus (SLE)
Emma Neary, MD
McGill University
Montreal, Quebec, Canada
No financial relationships with ineligible companies to disclose
PCA identified two principal components explaining 36.2% of the variance in ANAM throughputs and serum analytes. The first component (26.7% of the variance) was correlated with ANAM throughputs, with the strongest contribution from procedural reaction time. The second component (9.44% of the variance) was correlated with serum analyte measurements. The highest silhouette value was found for 2 (s=0.177) and 3 (s=0.176) clusters. Only 4% of patients were classified in the 3 cluster model, so a 2 cluster model was selected. Cluster 1 had low throughput scores representing CI, and Cluster 2 had higher throughput scores representing no CI. A significant difference was observed in mean serum S100A8/A9 (SMD=0.362), MMP-9 (SMD=0.178) and IL-6 (SMD=0.311) between the 2 clusters, reflected by the correlation between these analytes and the first principal component (Table 1). Serum levels of S100A8/A9, MMP-9, IL-6 had a strongly negative correlation between the Go No Go and Running Memory throughputs (Figure 2).
Conclusion: In patients with SLE, elevated serum S100A8/A9, MMP-9, and IL-6 are associated with low ANAM throughput scores, representing CI. These findings coincide with our recent study showing elevated S100A8/A9 and MMP-9 in patients with CI identified by the ACR-NB. Further studies are needed to uncover mechanistic relationships between these serum analytes and CI in SLE, and whether these analytes may represent valuable therapeutic targets to explore.
Figure 1: Correlation matrix for individual ANAM throughputs and serum analyte levels
Table 1: Standardized values for variables included in the Principal Component Analysis
Figure 2: Biplot of the first 2 principal components, with 2 clusters and association with analytes
E. Neary: None; C. Munoz-Grajales: None; J. Wither: AstraZeneca, 1, 2, Pfizer, 5; J. Diaz Martinez: None; M. Barraclough: None; K. Bingham: None; R. Kretzmann: None; M. Tartaglia: None; L. Ruttan: None; M. Choi: AbbVie/Abbott, 2, 6, Amgen, 2, 6, AstraZeneca, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, Celgene, 2, 6, Celltrion, 2, Eli Lilly, 2, 6, GlaxoSmithKlein(GSK), 2, Janssen, 2, 6, Mallinckrodt Pharmaceuticals, 2, Merck/MSD, 2, MitogenDx, 8, Organon, 2, Pfizer, 2, 6, Roche, 2, Werfen, 2; S. Appenzeller: None; S. Marzouk: None; D. Bonilla: None; P. Katz: None; D. Beaton: None; R. Green: None; L. Whittall Garcia: None; D. Gladman: AbbVie, 2, 5, Amgen, 2, 5, AstraZeneca, 2, BMS, 2, Celgene, 2, 5, Eli Lilly, 2, 5, Galapagos, 2, 5, Gilead, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5; Z. Touma: None.